DDX17 and colorectal carcinoma: Taken together, our findings indicated that DDX17 promoted metastasis and EMT progression in CRC through modulation of the miR-149-3p/CYBRD1 pathway, implicating DDX17 as a valuable predictor of prognosis in CRC patients and a potential therapeutic target for CRC.